

Zwitserleven

Factsheet

Zwitserleven Europees Aandelenfonds

Fund Profile

Zwitserleven Europees Aandelenfonds invests in companies in EU Member states, United Kingdom, Switzerland and Norway. The fund's financial return objective is to at least match the return of the benchmark while remaining within an established risk framework. To deliver on this objective, the asset manager deploys an active investment strategy, capitalising on anticipated market trends. At the same time, the fund promotes, among other, environmental or social characteristics. Investments are restricted to shares that meet the ESG criteria, as established by Cardano. An ESG score is assigned to all companies in the investment universe. The ESG score of the portfolio is always higher than the ESG score of the benchmark.


Performance and risk characteristics

	Fund	Benchmark
Standard deviation 36 m	8,45%	8,85%
Sharpe ratio 36m	1,42	1,21
Tracking error (ex-ante)	2,05%	
Active share	49,80	


Net Performance

	Fund	Benchmark
1 month	4,31%	3,11%
3 months	7,68%	6,83%
12 months	14,64%	15,63%
3 years, annualised ¹⁾	14,49%	13,18%
5 years, annualised ¹⁾	13,00%	12,06%
2026	4,31%	3,11%
2021	29,91%	25,13%
2022	-11,80%	-9,49%
2023	17,94%	15,83%
2024	11,93%	8,59%
2025	16,15%	19,39%

Price Index Fund



Sectors



Key Information as of January 31st 2026

Investment Institution	Zwitserleven Beleggingsfondsen
Currency	Euro
Inception Date	04-01-2005
Fund Manager	Cardano Asset Management N.V.
Country of Residence	The Netherlands
Benchmark	MSCI Europe Index Net EUR
Ongoing charges figure	0,040% (2025)
Obtainable via	Insurance product Zwitserleven (or Reaal)

Prices (Euro) and Facts

Net Asset Value End of Month	37,22
Highest price 12 months	37,22
Lowest price 12 months	27,97
Fund size	2.360.202.736
Outstanding participations	63.406.607
Dividend paying	No
SFDR classification	8

Fundamental Investment Principles (ESG-criteria)



Sustainability and Impact²



Instruments ESG-policy



Top Holdings

Asml Holding Nv	5,6%
Hsbc Holdings	3,7%
Astrazeneca	3,1%
Intesa Sanpaolo	2,8%
Roche Holding -Genuss	2,6%

Countries

